Meeting
2022 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Authors
Curtis Andrew Lachowiez
M.D. Anderson Cancer Center, Houston, TX
Curtis Andrew Lachowiez , Jacqueline Suen Garcia , Gautam Borthakur , Sanam Loghavi , Zhihong Zeng , George Dono Tippett , Tapan M. Kadia , Lucia Masarova , Musa Yilmaz , Abhishek Maiti , Prithviraj Bose , Koichi Takahashi , Elias Jabbour , Farhad Ravandi , Naval Guastad Daver , Guillermo Garcia-Manero , Paresh Vyas , Hagop M. Kantarjian , Marina Konopleva , Courtney Denton Dinardo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03471260
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7018)
DOI
10.1200/JCO.2022.40.16_suppl.7018
Abstract #
7018
Poster Bd #
249
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2022 ASCO Annual Meeting
Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.
First Author: David Andrew Sallman
Poster
2020 ASCO Virtual Scientific Program
Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
First Author: Charles Herbaux
Poster
2018 ASCO Annual Meeting
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
First Author: Paul A. Hamlin